Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 3, 2007, Pages 577-582

  Cattaneo, Marco ^a   Lecchi, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adenosine diphosphate; Aspirin; Cangrelor; Clopidogrel; P2Y12; Prostacyclin

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARC 69931 MX; BUCLADESINE; CANGRELOR; MRS 2500; PROSTACYCLIN; PURINE ANTAGONIST; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; THROMBIN; UNCLASSIFIED DRUG; 2 IODO N(6) METHYL (N) METHANOCARBA 2' DEOXYADENOSINE 3',5' BISPHOSPHATE; 2-IODO-N(6)-METHYL-(N)-METHANOCARBA-2'-DEOXYADENOSINE-3',5'-BISPHOSPHATE; ADENOSINE PHOSPHATE; ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC CMP; DEOXYADENOSINE PHOSPHATE; DIBUTYRYL CYCLIC 3',5' CYTIDINE MONOPHOSPHATE; DIBUTYRYL CYCLIC-3',5'-CYTIDINE MONOPHOSPHATE; DRUG DERIVATIVE; P2RY12 PROTEIN, HUMAN; PURINE P2 RECEPTOR; SEROTONIN;

ANTICOAGULATION; ARTICLE; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENYLATE CYCLASE; BLOOD PLATELETS; CYCLIC AMP; CYCLIC CMP; DEOXYADENINE NUCLEOTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPOPROSTENOL; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; SEROTONIN; THROMBIN;

EID: 34247566600     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02356.x     Document Type: Article

References (39)

1. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
2. Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 2005; 31: 150-61.
3. Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave J-P, Mannucci PM. Deficiency of [33P]2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997; 77: 986-90.
4. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: Further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20: E101-6
5. Cattaneo M, Canciani MT, Lecchi A, Kinlough-Rathbone RL, Packham MA, Mannucci PM, Mustard JF. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990; 75: 1081-6.
6. Cattaneo M, Akkawat B, Kinlough-Rathbone RL, Packham MA, Cimminiello C, Mannucci PM. Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin. Thromb Haemost 1994; 71: 91-4.
7. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-65.
8. Haslam RJ. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase. Ser Haematol 1973; 6: 333-50.
9. Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996; 7: 249-52.
10. Daniel JL, Dangelmaier C, Jin J, Kim YB, Kunapuli SP. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 1999; 82: 1322-6.
11. Hardy AR, Jones ML, Mundell SJ, Poole AW. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood 2004; 104: 1745-52.
12. Cattaneo M, Lecchi A, Lombardi R. Concomitant activation of both the P2Y1-driven Gq and the P2Y12-driven Gi patways is necessary for normal ADP-induced mobilization of cytoplasmic Ca2+. Hematol J 2003; 4 (Suppl. 2): 132.
13. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by G(i) family members in platelets. J Biol Chem 2002; 277: 23382-90.
14. Gachet C, Hechler B. The platelet P2 receptors in thrombosis. Sem Thromb Hemost 2005; 31: 162-7.
15. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 174-83.
16. Cattaneo M. Aspirin and clopidogrel. Efficacy safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
17. Cattaneo M. P2Y12 receptor antagonists: A rapidly expanding group of antiplatelet agents. Eur Heart J 2006; 27: 1038-47.
18. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 2005; 108: 180-92.
19. Best LC, Martin TJ, Russell RG, Preston FE. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature 1977; 267: 850-2.
20. van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Sem Thromb Hemost 2005; 31: 195-204
21. Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK, Jacobson KA. Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol 2004; 68: 1995-2002.
22. Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson K, Gachet C. MRS2500, a potent, selective and stable antagonist of the P2Y1 receptor, with strong antithrombotic activity in mice. J Pharmacol Exp Ther 2006; 316: 556-63.
23. Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204.
24. Cattaneo M, Canciani MT, Mannucci PM. Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)-effects of acetylsalicylic acid and external ionized calcium. Thromb Haemost 1985; 53: 221-4.
25. Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, Manning D, Poncz M, Lucki I, Blendy JA, Brass LF. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci USA 2000; 97: 9984-9.
26. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma Jr FJ, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107: 1591-8.
27. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
28. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5: 1199-202.
29. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999; 104: 1731-7.
30. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98: 3340-5.
31. Cattaneo M, Savage B, Ruggeri ZM. Effects of pharmacological inhibition of the P2Y1 and P2Y12 ADP receptors on shear-induced platelet aggregation and platelet thrombus formation on a collagen-coated surface under flow conditions. Blood 2001; 98: 239a
32. Cattaneo M. The P2 receptors and congenital platelet function defects. Sem Thromb Hemost 2005; 31: 168-73
33. Hass WK, Easton JD, Adams Jr HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-7.
34. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
35. Frelinger 3rd AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-96.
36. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705-9.
37. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 4: 813-9.
38. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
39. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, et al. CHARISMA Investigators. lopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.